The shares have climbed on every trading day so far in 2026. The streak looks set to continue. ...

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Core Insights - ImmunityBio's Anktiva has shown explosive sales growth, with a projected revenue increase from $15 million in 2024 to $113 million in 2025, representing a 700% growth year-over-year [2][5] - The stock price of ImmunityBio surged by 30.80% to close at $3.95, driven by strong preliminary earnings results and ongoing demand trends for Anktiva [2][5] - Recent approvals and positive clinical data for Anktiva in new indications, such as non-small cell lung cancer, indicate significant geographic expansion potential for the company [6] Company Performance - ImmunityBio's market capitalization stands at $3.0 billion, with a gross margin of 80.41% [2] - The trading volume reached 70.4 million shares, significantly above the three-month average of 13 million shares, indicating heightened investor interest [3] - The stock has experienced a dramatic decline of 89% since its IPO in 2015, highlighting its volatile history [3] Market Context - The S&P 500 and Nasdaq Composite saw minor gains of 0.27% and 0.25% respectively, while ImmunityBio outperformed its biotechnology peers, such as Incyte and Vertex Pharmaceuticals, which experienced declines [4]

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

ImmunityBio, Inc. (NASDAQ:IBRX) shares are up on Thursday as the company is reporting continued execution and sales momentum, with a significant increase in preliminary net product revenue.IBRX Reports 700% Revenue Surge in 2025ImmunityBio announced preliminary net product revenue for Anktiva reached approximately $113 million for fiscal 2025, reflecting a remarkable 700% increase year-over-year.Anktiva is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer carcinoma in situ (CIS).Fo ...

Financial Results Announcement - ImmunityBio, Inc. announced preliminary, unaudited financial results for the fiscal quarter and full year ending December 31, 2025[4] - The reported financial results are based on preliminary estimates and may differ materially from actual results to be disclosed in the Annual Report on Form 10-K[4] - The financial results are subject to the Company's financial closing procedures and final adjustments[4] - The Company has not yet finalized its operating results and financial position for the fiscal year ended December 31, 2025[4] Press Release Information - The press release regarding these results was issued on January 15, 2026[4] - The information provided in the press release is not deemed "filed" under the Securities Exchange Act of 1934[5] - The press release is included as Exhibit 99.1 in the Current Report on Form 8-K[6] Company Information - The Company is listed on The Nasdaq Global Select Market under the symbol IBRX[2] - The Company is incorporated in Delaware and has its principal executive offices in San Diego, California[1] - David C. Sachs serves as the Chief Financial Officer of ImmunityBio, Inc.[9]

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best penny stocks to buy for 2026. On December 16, ImmunityBio, Inc. (NASDAQ:IBRX) delivered positive clinical trial results for its ANKTIVA plus BCG treatment. The candidate drug being trialed in high-grade papillary non-muscle invasive bladder cancer demonstrated strong long-term efficacy in patients. H.C Wainwright Asserts Buy Stance as ImmunityBio, Inc. (IBRX) Achieves Positive Results on Bladder Cancer Treatment Pressmaster/Shutterstock.com The trial re ...

ImmunityBio (IBRX) shares added ~12% in the premarket on Wednesday after the Saudi Food and Drug Authority approved its best-selling immunotherapy, Anktiva, for certain patients with bladder cancer. According to the San Diego, California-based biotech, the SFDA’s approval allows the company to ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA® (nogapendekin alfa inbakicept) for use in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy. This marks the first approval of the C. ...